Abstract:
Provided are a dendrimer solid acid and a polymer electrolyte membrane using the same. The polymer electrolyte membrane includes a macromolecule of a dendrimer solid acid having ionically conductive terminal groups at the surface thereof and a minimum amount of ionically conductive terminal groups required for ionic conduction, thus suppressing swelling and allowing a uniform distribution of the dendrimer solid acid, thereby improving ionic conductivity. Since the number of ionically conductive terminal groups in the polymer electrolyte membrane is minimized and the polymer matrix in which swelling is suppressed is used, methanol crossover and difficulties of outflow due to a large volume may be reduced, and a macromolecule of the dendrimer solid acid having the ionically conductive terminal groups on the surface thereof is uniformly distributed. Accordingly, ionic conductivity is high and thus, the polymer electrolyte membrane shows good ionic conductivity even in non-humidified conditions.
Abstract:
Compounds of general formula (I), stereosiomers and pharmaceutically acceptable salts thereof, wherein each of Z and Z' are independently H or F; Q is (a), CH(OH), (b); X is H, Br, Cl, F or CF.sub.3 ; Y is H, Br, Cl, F, OH, OR.sub.5, OC(O)R.sub.4, N.sub.3, CN, NO.sub.2, SO.sub.3 H, CO.sub.2 R.sub.4, NH.sub.2, NHR.sub.9, NR.sub.9 R'.sub.9, C(R.sub.6)(R.sub.7)(V'R.sub.8) or C(O)R.sub.7, provided that when both Z and Z' are F, then Y is H or F; V and V' are each independently CH.sub.2 or O; R.sub.1 is H or CH.sub.3 ; R.sub.2, R.sub.9 and R'.sub.9 are each independently (C.sub.1-6)alkyl, or R.sub.2 and V--R.sub.3 taken together with the carbon atom to which they are attached form a 3-6 membered ring; R.sub.3, R.sub.6, R.sub.7 and R.sub.8 are each independently H, (C.sub.1-6)alkyl, or (C.sub.3-6)cycloalkyl; R.sub.4 is H, (C.sub.1-10)alkyl, (C.sub.0-4)alkylene aryl or (C.sub.3-8)cycloalkyl; and R.sub.5 is (C.sub.1-10)alkyl, benzyl, phenethyl or (C.sub.3-6)cycloalkyl, possess anticholinesterase activity and may be used in the treatment of Degenrativa Dementias.
Abstract:
A method for inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachements to the ring, with polar substitutent having a terminal carboxylate, phosphate, or sulfonate groups, including esters and amides which are cleavable in vivo. The compound may be administered orally, or topically, e.g., for treatment of herpes virus.
Abstract:
A method of inhibiting thrombus formation in a mammalian subject. The method involves administering to the subject a therapeutically effective dose of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachments to the ring, with polar substituents having terminal sulfonate groups, including esters and amides which are cleavable in vivo.
Abstract:
A method of inhibiting cell infection by herpes simplex virus-1 or -2. The method includes contacting the virus with a macrocyclic chromotropic acid compound, in an amount effective to inhibit cell infectivity of the virus.
Abstract:
4-alkoxy-2-hydroxybenzophenone-5-sulfonic acids of the general formula I ##STR1## where R.sup.1 is C.sub.1 -C.sub.20 -alkyl which is unsubstituted or substituted by halogen, cyanao, hydroxyl, C.sub.1 -C.sub.20 -alkoxy, C.sub.2 -C.sub.20 -alkoxycarbonyl, acyloxy and/or phenyl which is unsubstituted or substituted by C.sub.1 -c.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy and/or halogen, R.sup.2 and R.sup.3 independently of one another are each hydrogen, halogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.4 -haloalkyl, C.sub.3 -C.sub.8 -cycloalkyl, C.sub.4 -C.sub.12 -cycloalkylalkyl, cyano, hydroxyl or hydroxyethyl or are each phenoxy, C.sub.7 -C.sub.10 -phenalkyl or phenyl which is unsubstituted or substituted by C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy and/or halogen, and R.sup.4 is hydrogen or sulfo, are prepared by reacting a 4-alkoxy-2-hydroxybenzophenone of the general formula II ##STR2## with chlorosulfonic acid at from -20.degree. to +100.degree. C., by a novel and improved process in which the reaction is carried out in an aliphatic, cycloaliphatic and/or aromatic carboxylate as solvent.
Abstract:
The invention consists in an improved process for the preparation of salts of benzaldehyde-2,4-disulfonic acid from 2,4-dichlorobenzaldehyde. In the process 2,4-di-chlorobenzaldehyde is reacted with an aqueous solution of an alkali metal or alkaline earth sulfite and/or hydrogensulfite for a reaction time of less than 7 hours at 140.degree.-180.degree. C. to form the corresponding salt of benzaldehyde-2,4-disulfonic acid with high yield. The product has application in the electroplating industry and in the preparation triphenylmethane dyestuffs.
Abstract:
A sweetening agent in the form of a 1,3-diphenyl-propanone-1 derivative of the formula ##SPC1##Wherein R is hydrogen, hydroxyl, alkoxy or carboxyl-substituted, sulphonyl-substituted, phosphonyl-substituted, dialkylamino-substituted, trialkyl ammonium-substituted alkoxy; R.sup.1 is hydrogen or a hydrophylic group but both R and R.sup.1 are not both hydrogen; R.sup.2 and R.sup.3 are hydroxyl or alkoxy.